Article in Molecular cancer research : MCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Matthew J BernardMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-2417-7508
Andrea GallardoDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0000-2236-3337
Angel RuizMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-5956-6899
Johnny A DiazMolecular Biology Interdepartmental Program, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-7289-6059
Nicholas M NunleyDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0007-2368-1653
Rachel N DoveDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0004-9573-9840
Shile ZhangDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-4345-9917
Ernie LeeDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0002-8733-4611
Kylie Y HeeringDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0006-1839-277X
Grigor VaruzhanyanDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-6165-0857
Sachi BopardikarDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0008-8103-0020
Takao HashimotoDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-7205-0897
Raag AgrawalDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-8222-3117
Chad M SmithDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0009-0003-3171-2545
Blake R WildeJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8372-3954
Nedas MatulionisDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0001-7624-3090
Helen M RichardsDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0009-0008-4328-488X
Sandy Che-Eun S LeePulmonary and Critical Care Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-7691-8104
Marina N SharifiCarbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0003-0128-3033
Joshua M LangCarbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-0943-8872
Shuang G ZhaoCarbone Cancer Center, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-9166-6507
Owen N WitteDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-4461-4533
Michael C HaffnerDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, Washington.ORCID 0000-0003-0809-6425
David B ShackelfordJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8270-898X
Paul C BoutrosDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0553-7520
Heather R ChristofkJonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0002-8662-4425
Andrew S GoldsteinDepartment of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0434-9149
Funding
Tumor Immunology and Immunotherapy (TII)P30CA016042 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2025
$29.3M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2002 to 2005
$8.7M
UCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2024 to 2025
$3.5M
TUMOR CELL SURFACES AND CHROMOSOMEST32CA009056 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 1985 to 2025
$2.8M
Virginia-UCLA-Toronto Biomarker Characterization CenterU2CCA271894 · OLD DOMINION UNIVERSITY · 2025 to 2025
$843k
Germline Determinants of Prostate Cancer EvolutionR01CA270108 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$729k
Augmenting PSMA expression to enhance PSMA directed therapeutic efficacyR37CA286450 · FRED HUTCHINSON CANCER CENTER · 2025 to 2025
$668k
In vivo imaging of mitochondria structure and function in therapy resistant lung tumorsR01CA267721 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$620k
Imaging mitochondrial heterogeneity in LKB1 mutant lung cancerR01CA208642 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$429k
Training CoreTL1DK132768 · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2025 to 2025
$390k
Center for Cancer Research (CCR) P30CA016042Center for Cancer Research (CCR) R01CA208642Center for Cancer Research (CCR) R01CA267721Center for Cancer Research (CCR) R01CA270108Center for Cancer Research (CCR) R37CA286450Center for Cancer Research (CCR) U2CCA271894DOD Prostate Cancer Research Program (PCRP) HT94252310379DOD Prostate Cancer Research Program (PCRP) PC220240DOD Prostate Cancer Research Program (PCRP) W81XWH2210247DOD Prostate Cancer Research Program (PCRP) W81XWH2210751Doris Duke Charitable Foundation (DDF) 2021184National Center for Advancing Translational Sciences (NCATS) UL1TR001881National Institute of General Medical Sciences (NIGMS) T32GM152342NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS R01 CA208642NCI NIH HHS R01 CA267721NCI NIH HHS R01 CA270108NCI NIH HHS R37 CA286450NCI NIH HHS T32 CA009056NCI NIH HHS U2C CA271894NIDDK NIH HHS TL1 DK132768NIGMS NIH HHS T32 GM152342Prostate Cancer Foundation (PCF)
6 · The paper itself
Abstract
As cancer cells evade therapeutic pressure and adopt alternate lineage identities not commonly observed in the tissue of origin, they likely adopt alternative metabolic programs to support their evolving demands. Targeting these alternative metabolic programs in distinct molecular subtypes of aggressive prostate cancer may lead to new therapeutic approaches to combat treatment resistance. We identify the poorly studied metabolic enzyme oxoglutarate dehydrogenase-like (OGDHL), named for its structural similarity to the tricarboxylic acid (TCA) cycle enzyme oxoglutarate dehydrogenase, as an unexpected regulator of tumor growth, treatment-induced lineage plasticity, and DNA damage in prostate cancer. Although OGDHL has been described as a tumor suppressor in various cancers, we find that its loss impairs prostate cancer cell proliferation and tumor formation. Loss of OGDHL reduces nucleotide synthesis, induces accumulation of the DNA damage response marker γH2AX, and alters androgen receptor inhibition-induced plasticity. Our data suggest that OGDHL has minimal impact on TCA cycle activity and that mitochondrial localization is not required for its regulation of nucleotide metabolism. Finally, we demonstrate that OGDHL expression is tightly correlated with neuroendocrine (NE) differentiation in clinical prostate cancer and that knockdown of OGDHL impairs the growth of cell line models of NE prostate cancer. These findings underscore the importance of investigating poorly characterized metabolic genes as potential regulators of distinct molecular subtypes of aggressive cancer. IMPLICATIONS: OGDHL emerged as an unexpected metabolic dependency associated with lineage plasticity and NE differentiation, implicating poorly studied metabolic enzymes as potential targets for treatment-resistant prostate cancer.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
OGDHL Promotes Prostate Cancer Progression and Regulates Neuroendocrine Marker Expression and Nucleotide Abundance. · full record | Socratic